Polypill Strategy in Secondary Cardiovascular Prevention.
José María CastellanoStuart J PocockDeepak L BhattAntonio J QuesadaRuth OwenAntonio Fernandez-OrtizPedro Luis SánchezFrancisco Marin OrtuñoJose M Vazquez RodriguezAlexandra Domingo-FernándezIñigo LozanoMaria C RoncaglioniMarta BavieraAndreana ForestaLuisa Ojeda-FernandezFurio ColivicchiStefania A Di FuscoWolfram DoehnerAntje MeyerFrançois SchieleFiona EcarnotAleš LinhartJean-Claude LubandaGyorgy BarcziBela MerkelyPiotr PonikowskiMarta KasprzakJuan M Fernandez AlviraVicente AndresHector BuenoTimothy CollierFrans Van de WerfPablo PerelMoises Rodriguez-ManeroAngeles Alonso GarciaMarco ProiettiMikkel M SchoosTabassome SimonJose Fernandez FerroNicolas LopezEttore BeghiYannick BejotDavid VivasAlberto Cordero-FortBorja IbañezValentin Fusternull nullPublished in: The New England journal of medicine (2022)
Treatment with a polypill containing aspirin, ramipril, and atorvastatin within 6 months after myocardial infarction resulted in a significantly lower risk of major adverse cardiovascular events than usual care. (Funded by the European Union Horizon 2020; SECURE ClinicalTrials.gov number, NCT02596126; EudraCT number, 2015-002868-17.).